Drug intelligence / Profile preview

BB710 Metabolite 1

Development stage: Unknown
Lead developer: BalinBac Therapeutics
Modality: Small Molecules
Administration: Inhalation, Oral

Overview

**BB710 Metabolite 1** is an uncharacterized BalinBac Therapeutics program listed in supplied pipeline context as a COVID-19 antiviral-related metabolite associated with the BB-700 series. The series is described by the sponsor as using combinations of repurposed generic drugs with complementary antiviral mechanisms and oral and inhalation delivery approaches. The exact chemical identity, active ingredients, molecular targets, and clinical evidence for BB710 Metabolite 1 have not been publicly substantiated.

Beyond the preview

Go deeper on BB710 Metabolite 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BB710 Metabolite 1.

Explore the full profile